InvestSMART

Aroa Biosurgery Limited (ASX:ARX)

ALERT: Price-sensitive ASX Announcement for ARX
Current share price for ARX : $0.570 0 (0%)+
Announcement
Release
30 Mar 2026 9:15AM
Price at Release
$0.570
Full Release
download
Summary
Aroa Biosurgery Limited announced the completion of its Symphony randomised controlled trial (RCT), which evaluated Symphony against standard care for diabetic foot ulcers. The trial, conducted across multiple US sites and including up to 150 patients, achieved its primary endpoint, indicating that Symphony effectively aids in healing more diabetic foot ulcers within 12 weeks than standard care. Symphony, which integrates AROA ECM™ with hyaluronic acid, is specifically designed for hard-to-heal wounds. The successful trial results are expected to bolster Symphony's clinical adoption and support US reimbursement policy adherence. The company anticipates publishing the full study results, reinforcing Symphony's clinical value in treating chronic, complex wounds.
Key Points
  • Aroa Biosurgery Limited completed its Symphony randomised controlled trial (RCT).
  • The trial compared Symphony with standard of care in diabetic foot ulcers.
  • Preliminary findings indicate that the primary endpoint of the trial was met.
  • Symphony is designed to aid in healing difficult wounds like diabetic foot ulcers using AROA ECM™ technology.
  • The trial was conducted at multiple US sites with recruitment up to 150 patients.
  • Results support clinical adoption of Symphony and may influence future US reimbursement requirements.
  • Publication of full study results is anticipated to enhance clinical evidence base.
  • The study's success underscores the potential of Symphony in managing chronic, complex wounds.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.